TFA
CYTK icon

Transamerica Financial Advisors’s Cytokinetics CYTK Stock Holding History

Transamerica Financial Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$681 Sell
8
-1
-11% -$72 ﹤0.01% 1603
2026
Q1 		$593 Buy
9
+8
+800% +$508 ﹤0.01% 1447
2025
Q4 		$64 Hold
1
– – ﹤0.01% 1738
2025
Q3 		$55 Buy
+1
New +$41 ﹤0.01% 1573

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Transamerica Financial Advisors's CYTK Position: Q2 2026 in Review

Transamerica Financial Advisors reduced its Cytokinetics (CYTK) stake by 11% in Q2 2026, selling an estimated $72 and leaving 8 shares worth $681. The position accounts for ﹤0.01% of the portfolio, ranked #1603.

Transamerica Financial Advisors first reported a position in CYTK in Q3 2025 and has held it in 4 quarters since. 480 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Transamerica Financial Advisors held 8 shares of Cytokinetics worth $681 as of Q2 2026.
  • Transamerica Financial Advisors sold 1 Cytokinetics share in Q2 2026, an estimated $72.
  • Cytokinetics made up ﹤0.01% of Transamerica Financial Advisors's portfolio in Q2 2026, its #1603 holding.
  • Transamerica Financial Advisors first reported a position in Cytokinetics in Q3 2025 and has held it in 4 quarters since.
  • 480 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.